Elite in Major Depression

Dr. Scott T. Aaronson

Psychiatry
6501 N Charles St, 
Baltimore, MD 
Accepting New Patients
Elite in Major Depression
6501 N Charles St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Aaronson is a Psychiatrist in Baltimore, Maryland. Dr. Aaronson is rated as an Elite provider by MediFind in the treatment of Major Depression. His top areas of expertise are Major Depression, Bipolar Disorder (BPD), Post-Traumatic Stress Disorder (PTSD), Obsessive-Compulsive Disorder (OCD), and Deep Brain Stimulation. Dr. Aaronson is currently accepting new patients.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles and participated in 2 clinical trials in the study of Major Depression.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

6501 N Charles St, Baltimore, MD 21204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
Enrollment Status: Completed
Publish Date: August 12, 2025
Intervention Type: Device
Study Phase: Not Applicable
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Device
Study Phase: Not Applicable
Escitalopram for Agitation in Alzheimer's Disease
Escitalopram for Agitation in Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Escitalopram
Study Phase: Phase 3
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
Enrollment Status: Terminated
Publish Date: December 20, 2024
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Enrollment Status: Completed
Publish Date: April 24, 2023
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Enrollment Status: Unknown
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
An Open Label Trial of TMS Therapy for Bipolar Depression
An Open Label Trial of TMS Therapy for Bipolar Depression
Enrollment Status: Completed
Publish Date: June 01, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Multicenter, Double-Blind, Sham-Controlled Adaptive Design Study to Confirm the Safety and Efficacy of NEST sTMS in Subjects With Major Depressive Disorder Who Have Not Responded to at Least One Antidepressant Medication in the Current Episode
A Prospective, Multicenter, Double-Blind, Sham-Controlled Adaptive Design Study to Confirm the Safety and Efficacy of NEST sTMS in Subjects With Major Depressive Disorder Who Have Not Responded to at Least One Antidepressant Medication in the Current Episode
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Device
Study Phase: Not Applicable
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Enrollment Status: Completed
Publish Date: October 24, 2018
Intervention Type: Drug
View 12 Less Clinical Trials

70 Total Publications

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
Journal: Journal of affective disorders
Published: October 11, 2025
Similar Doctors
Distinguished in Major Depression
Dr. Chima N. Asikaiwe
Psychiatry
Distinguished in Major Depression
Dr. Chima N. Asikaiwe
Psychiatry

Greathope Psychiatry PLLC

6314 Windsor Mill Rd, Suite 100, 
Gwynn Oak, MD 
 (7.4 miles away)
469-778-0263
Languages Spoken:
English, American Sign Language, Bengali, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Chima Asikaiwe is a Psychiatrist in Gwynn Oak, Maryland. Dr. Asikaiwe is rated as an Advanced provider by MediFind in the treatment of Major Depression. His top areas of expertise are Major Depression, Generalized Anxiety Disorder (GAD), Seasonal Affective Disorder (SAD), and Bipolar Disorder (BPD). Dr. Asikaiwe is currently accepting new patients.

Distinguished in Major Depression
Dr. Francis M. Mondimore
Psychiatry
Distinguished in Major Depression
Dr. Francis M. Mondimore
Psychiatry
600 N Wolfe St, 
Baltimore, MD 
 (6.6 miles away)
410-955-5104
Languages Spoken:
English

Francis Mondimore is a Psychiatrist in Baltimore, Maryland. Dr. Mondimore is rated as a Distinguished provider by MediFind in the treatment of Major Depression. His top areas of expertise are Bipolar Disorder (BPD), Major Depression, Post-Traumatic Stress Disorder (PTSD), and Schizophrenia.

Distinguished in Major Depression
Dr. Andrei A. Pikalov
Psychiatry
Distinguished in Major Depression
Dr. Andrei A. Pikalov
Psychiatry
14207 Reed Farm Way, 
North Potomac, MD 
 (38.9 miles away)
240-422-4953
Languages Spoken:
English
See accepted insurances

Andrei Pikalov is a Psychiatrist in North Potomac, Maryland. Dr. Pikalov is rated as an Elite provider by MediFind in the treatment of Major Depression. His top areas of expertise are Bipolar Disorder (BPD), Schizophrenia, and Major Depression.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aaronson's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile